Interactive effect of sarcopenia and falls on vertebral osteoporotic fracture in patients with rheumatoid arthritis

Tong, Jing-Jing; Xu, Shengqian; Wang, Jianxiong; Zong, He-Xiang; Chu, Yi-ran; Chen, Keming; Teng, Yuzhu

doi:10.1007/s11657-021-01017-1

Cited by 4 publications

(18 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After contacting the authors, we learned that 4 studies included some overlap in their respective patient samples, so these studies were included only in descriptive analysis but excluded from pooled analysis. [20][21][22][23]…”

Section: Resultsmentioning

confidence: 99%

“…The duration of studies ranged from 7 to 58 months, with a median duration of 26.5 months. The country of origin of the greatest number of studies was China (6 studies), 7,[20][21][22][23]28 followed by Japan (5 studies), 24,25,[29][30][31] and Germany, 26 New Zealand, 32 South Korea, 33 Spain, 34 and Turkey 27 each with 1 study. Eight studies included both RA patients and healthy control subjects, and 8 studies [24][25][26][28][29][30][31]33 included RA patients only (see Supplementary Table 2, http://links.lww.com/RHU/A568).…”

Section: Characteristics Of the Studiesmentioning

confidence: 99%

“…Eight studies included both RA patients and healthy control subjects, and 8 studies [24][25][26][28][29][30][31]33 included RA patients only (see Supplementary Table 2, http://links.lww.com/RHU/A568). Eight studies were rated as having low risk of bias, [20][21][22]25,29,[33][34][35] and 8 studies with medium risk of bias. 23,24,[26][27][28][30][31][32] In addition, there may be a high risk of publication bias due to the limited number of studies published in this area (Fig.…”

Section: Characteristics Of the Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Risk Factors and Clinical Outcomes Associated With Sarcopenia in Rheumatoid Arthritis

Tam

Wong-Pack

Liu³

et al. 2023

J Clin Rheumatol

View full text Add to dashboard Cite

Sarcopenia is underrecognized in patients with rheumatoid arthritis (RA). Risk factors of sarcopenia and its impact on outcomes in RA patients are relatively unknown. We conducted a systematic review to identify factors and outcomes associated with sarcopenia in RA. We conducted this review according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines. We searched PubMed, Embase, CINAHL, and Web of Science databases by combining the following search concepts: (1) RA and (2) sarcopenia. Articles were included if they included RA patients, assessed for sarcopenia using a consensus working group definition, and assessed for clinical outcomes. Meta-analysis was performed using studies that shared the same sarcopenia definition and consistency in reporting patient or disease variables. Our search identified 3602 articles. After removal of duplicates, title and abstract screen, and full-text review, 16 articles were included for final analysis. All studies had observational study designs. The pooled prevalence of sarcopenia ranged from 24% to 30%, depending on the criteria for sarcopenia used. Factors associated with sarcopenia included higher 28-joint Disease Activity Scale scores (+0.39; 95% confidence interval, +0.02 to +0.77) and baseline methotrexate use (odds ratio, 0.70; 95% confidence interval, 0.51-0.97). Baseline glucocorticoid use had a positive correlation with sarcopenia in multiple studies. Several studies found lower bone mineral density and higher incidence of falls and fractures in patients with sarcopenia. Sarcopenia is prevalent in RA, and it may be associated with higher RA disease activity, lower bone mineral density, and increased falls and fractures. Therefore, early screening of sarcopenia in RA patients is important to incorporate into clinical rheumatology practice.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Characteristics Of the Studiesmentioning

confidence: 99%

Section: Characteristics Of the Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Risk Factors and Clinical Outcomes Associated With Sarcopenia in Rheumatoid Arthritis

Tam

Wong-Pack

Liu³

et al. 2023

J Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…lean mass (kg) Method of BC assay Pre-DAS-28 Post-DAS-28 Tournadre [ 23 ] France M/F 2017 21 57.8 ± 10.5 Tocilizumab 12 months NI Lean mass App. lean mass Baseline: 42.1 (± 11.1) Final: 43.2 (±11.3) Baseline: 17.7 (± 5.4) Final: 18.7 (± 5.6) DEXA 4.94 ± 1.25 2.8 ± 1.5 Toussirot [ 22 ] France M/F 2020 107 56.6 ± 13.5 Tocilizumab 12 months 8 mg/kg (monthly) Lean mass Baseline: 40.76 (± 8.4) Final: 42.11 (± 8.9) – DEXA 4.93 ± 1.3 2.3 ± 1.3 Ferraz-Amaro [ 24 ] Spain M/F 2011 16 50.8 ± 14.6 Anti-TNF 12 months Varied Lean mass Baseline: 53.7 (NI) Final: 50.5 (NI) – BIA 5.58 ± 0.87 2.89 ± 1.37 Metsios [ 25 ] United Kingdom M/F 2007 20 61.1 ± 6.8 Anti-TNF 3 months NI Lean mass Baseline: 50.9 (± 12.7) Final: 51.1 (± 12.5) – BIA 5.66 ± 0.7 3.59 ± 0.7 Chikugo [ 26 ] Japan F 2018 4 55.3 ± 19.5 Tofacitinib 6 months NI App. lean mass – Baseline: NI Final: 20.4 (± 4.0) BIA 5.1 ± 0.8 NI Al Khayyat [ …”

Section: Resultsmentioning

confidence: 99%

“…However, tocilizumab, an IL-6 inhibitor, may improve muscle mass by increasing appendicular lean mass and total lean mass in RA patients [ 8 ]. Also, glucocorticoids (CG) that can control disease activity in RA have known negative effects on the skeletal muscle in RA patients [ 24 , 25 ]. Targeting inflammatory cytokines seems to have a positive role in muscle wasting.…”

Section: Introductionmentioning

confidence: 99%

The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis

et al. 2022

View full text Add to dashboard Cite

Introduction Rheumatoid arthritis (RA) is an autoimmune disease, characterized by chronic and systemic inflammation. Besides, it is known that RA patients may present several comorbidities, such as sarcopenia, a condition where patients present both muscle mass and muscle quality impairment. RA treatment is mostly pharmacological and consists in controlling systemic inflammation and disease activity. Despite that, the effect of pharmacological treatment on sarcopenia is not well characterized. Objective To summarize the effects of disease-modifying anti-rheumatic drugs (DMARDs) on skeletal muscle tissue in rheumatoid arthritis (RA) patients. Methods A systematic review of randomized clinical trials and observational studies was conducted using MEDLINE, Embase, Cochrane Library, and Web of Science. We selected studies with rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs (DMARDs) that analyzed muscle mass parameters such as lean mass and appendicular lean mass. Methodological quality was assessed using the Newcastle-Ottawa Quality Assessment Scale. Standardized mean difference (SMD) and 95% confidence intervals (CI) were set. A meta-analysis of observational studies was performed using the R software, and we considered significant statistics when p < 0.05. Results Nine studies were included in this systematic review. In the meta-analysis, DMARD treatment had no positive difference (p = 0.60) in lean mass. In the same way, in the appendicular lean mass parameter, our results showed that DMARDs did not have changes between baseline and post-treatment analysis (p = 0.93). Conclusion There is no evidence of a significant effect of DMARD therapy, either synthetic or biological, on muscle mass. However, this association should be investigated with more studies.

show abstract

The Effect of Rheumatoid Arthritis on Features Associated with Sarcopenia: A Mendelian Randomization Study

Ding,

Jiang,

Zhangwang

et al. 2024

Calcif Tissue Int

View full text Add to dashboard Cite

Interactive effect of sarcopenia and falls on vertebral osteoporotic fracture in patients with rheumatoid arthritis

Cited by 4 publications

References 38 publications

Risk Factors and Clinical Outcomes Associated With Sarcopenia in Rheumatoid Arthritis

Risk Factors and Clinical Outcomes Associated With Sarcopenia in Rheumatoid Arthritis

The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis

The Effect of Rheumatoid Arthritis on Features Associated with Sarcopenia: A Mendelian Randomization Study

Contact Info

Product

Resources

About